Latest News

Caris’ studies show use of molecular profiling to develop oncology therapies

US-based Caris Life Sciences has reported positive data from two studies conducted for the validation of its tumour molecular profiling approach to guide the development of therapeutic...

Caris’ studies show use of molecular profiling to develop oncology therapies

UCL research indicates use of diabetes drug in Parkinson’s disease

UCL research indicates use of diabetes drug in Parkinson’s disease

Researchers find South African child in HIV remission for nine years

Researchers find South African child in HIV remission for nine years

New Oxford study indicates bleeding risk by aspirin in elderly patients

New Oxford study indicates bleeding risk by aspirin in elderly patients

resTORbio begins Phase IIb mTORC1 inhibitors trial

US-based clinical-stage biopharmaceutical company PureTech Health subsidiary resTORbio has initiated a Phase IIb study of its mechanistic target of rapamycin complex 1 (mTORC1)...

resTORbio begins Phase IIb mTORC1 inhibitors trial

BMS and Apexigen to assess Opdivo + APX005M combination for NSCLC

Bristol-Myers Squibb (BMS) has entered a clinical collaboration with biopharmaceutical firm Apexigen to assess the combination of Opdivo (nivolumab) with APX005M for the treatment of advanced...

BMS and Apexigen to assess Opdivo + APX005M combination for NSCLC

Clinical study suggests efficacy of modafinil to improve memory in patients with depression

Clinical study suggests efficacy of modafinil to improve memory in patients with depression

Sanaria reports positive results from Phase II trial of PfSPZ Vaccine for malaria

Sanaria reports positive results from Phase II trial of PfSPZ Vaccine for malaria

CalciMedica begins Phase I trials for CRAC channel inhibitor

US-based bio-pharmaceutical company CalciMedica has initiated the Phase I safety studies in healthy volunteers of a new calcium release-activated calcium (CRAC) channel inhibitor, CM4620,...

CalciMedica begins Phase I trials for CRAC channel inhibitor

M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent

Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan,...

M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent

Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune

Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in...

Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune

NIAID-funded clinical trial to evaluate shorter-duration antibiotics in children

Five medical centres in the US are planning to conduct the SCOUT-CAP clinical trial to determine the efficacy of shorter course of antibiotics in treating community-acquired pneumonia (CAP)...

NIAID-funded clinical trial to evaluate shorter-duration antibiotics in children

NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa

NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa

M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici

Allergen has acquired Chase Pharmaceuticals Corporation from New Rhein Healthcare Investors for a purchase consideration of...

M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici

Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics

Rosetta Genomics and Sheba Medical Centre have entered a research agreement to develop and evaluate the efficacy of microRNA biomarkers to analyse the response of the drug nivolumab in lung...

Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease

Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn’s disease...

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease

Washington University and Harvard Medical School report positive topical immunotherapy trial results

Washington University and Harvard Medical School report positive topical immunotherapy trial results

Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study

Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210. ...

Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study

M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry

Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis...

M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry

Deals this week: Pfizer, Peakdale Molecular, Selexis

Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple...

Deals this week: Pfizer, Peakdale Molecular, Selexis

Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics

GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy...

Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics